Effect of immune drugs to treat acute viral nasopharyngitis

The task in treating acute nasopharyngitis (ANP) deals with reducing the disease symptoms and the risk of complications. The lack of reliable antiviral drugs makes it important to search for appropriate medicines among other pharmacotherapeutic groups.The study involves a comparative analysis of the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E. V. Bezrukova, E. V. Vorobeychikov, V. G. Konusova, A. V. Sosunov, M. M. Shamtsyan, S. A. Artyushkin, A. S. Simbirtsev
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2021
Materias:	intranasal interferon α2b β-d-glucans acute nasopharyngitis il-1β il-1ra Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/4223c9fb4215442ea3763d977e9931ad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4223c9fb4215442ea3763d977e9931ad
record_format	dspace
spelling	oai:doaj.org-article:4223c9fb4215442ea3763d977e9931ad2021-11-18T08:03:51ZEffect of immune drugs to treat acute viral nasopharyngitis1563-06252313-741X10.15789/1563-0625-EOI-2300https://doaj.org/article/4223c9fb4215442ea3763d977e9931ad2021-11-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/2300https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThe task in treating acute nasopharyngitis (ANP) deals with reducing the disease symptoms and the risk of complications. The lack of reliable antiviral drugs makes it important to search for appropriate medicines among other pharmacotherapeutic groups.The study involves a comparative analysis of the efficiency and estimates potential: the recombinant interferon α2b and the compound containing fungal β-D-glucans used in treat ANPThe studies involved patients with ANP from 18 to 55 years old. As many as 152 people were examined including the following: 38 were practically healthy people (group 1); and 114 patients wuth ANP: 38 people (group 2) was subject to a standard therapy (vasoconstrictor nasal drops, nasal cavity irrigation using 0.1% Miramistine solution, gargling using the Furacilin solution); forty people (group 3) were administered application of intranasal interferon α2b of 105 IU, it was delivered with a spray into each nasal passage twice a day; 36 people (group 4) were administered an immunotropic drug containing β-D-glucans orally twice a day. The duration of drug administration lasted 7 days. Polymerase chain reaction (PCR) was used to identify the ANP etiological factor. Concentrations of cytokines IL-1β, IL-1ra were estimated using enzyme immunoassay (ELISA) technique. Clinical efficiency was assessed through score approach. The following symptoms were taken into account: general malaise, sore throat, character of nasal discharge, and the difficulty of nasal breathing. The results of the study were analyzed using parametric and nonparametric statistical methods. In 60.0% the nasal secretions of patients revealed RV. The distribution of cytokine concentrations in nasal secretions in group 1 indicated that the concentration of IL-1β was in the range of 20.0-25.0 pg/ml, and the concentration of IL-1ra was about 1250.0-2500.0 pg/ml. Developing ANP stimulated an increase in IL-1β concentration up to 30.0-70.0 pg/ml in nasal secretions of patients without affecting IL-1ra concentrations. On day 7 of treatment, the cytokine concentrations among the patients treated using the immunotropic drugs were the same as in the group of healthy individuals. There were no significant changes in cytokine production on day 7 in the group of patients undergoing the standard treatment. Application of proposed immunobiological medicines to ANP does not result in overproduction of proinflammatory cytokine IL-1β in nasal secretion. This confirms that these drugs are promising in the treating strategy including reduction of the risk of developing complications.E. V. BezrukovaE. V. VorobeychikovV. G. KonusovaA. V. SosunovM. M. ShamtsyanS. A. ArtyushkinA. S. SimbirtsevSPb RAACIarticleintranasal interferon α2bβ-d-glucansacute nasopharyngitisil-1βil-1raImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 23, Iss 5, Pp 1151-1164 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	intranasal interferon α2b β-d-glucans acute nasopharyngitis il-1β il-1ra Immunologic diseases. Allergy RC581-607
spellingShingle	intranasal interferon α2b β-d-glucans acute nasopharyngitis il-1β il-1ra Immunologic diseases. Allergy RC581-607 E. V. Bezrukova E. V. Vorobeychikov V. G. Konusova A. V. Sosunov M. M. Shamtsyan S. A. Artyushkin A. S. Simbirtsev Effect of immune drugs to treat acute viral nasopharyngitis
description	The task in treating acute nasopharyngitis (ANP) deals with reducing the disease symptoms and the risk of complications. The lack of reliable antiviral drugs makes it important to search for appropriate medicines among other pharmacotherapeutic groups.The study involves a comparative analysis of the efficiency and estimates potential: the recombinant interferon α2b and the compound containing fungal β-D-glucans used in treat ANPThe studies involved patients with ANP from 18 to 55 years old. As many as 152 people were examined including the following: 38 were practically healthy people (group 1); and 114 patients wuth ANP: 38 people (group 2) was subject to a standard therapy (vasoconstrictor nasal drops, nasal cavity irrigation using 0.1% Miramistine solution, gargling using the Furacilin solution); forty people (group 3) were administered application of intranasal interferon α2b of 105 IU, it was delivered with a spray into each nasal passage twice a day; 36 people (group 4) were administered an immunotropic drug containing β-D-glucans orally twice a day. The duration of drug administration lasted 7 days. Polymerase chain reaction (PCR) was used to identify the ANP etiological factor. Concentrations of cytokines IL-1β, IL-1ra were estimated using enzyme immunoassay (ELISA) technique. Clinical efficiency was assessed through score approach. The following symptoms were taken into account: general malaise, sore throat, character of nasal discharge, and the difficulty of nasal breathing. The results of the study were analyzed using parametric and nonparametric statistical methods. In 60.0% the nasal secretions of patients revealed RV. The distribution of cytokine concentrations in nasal secretions in group 1 indicated that the concentration of IL-1β was in the range of 20.0-25.0 pg/ml, and the concentration of IL-1ra was about 1250.0-2500.0 pg/ml. Developing ANP stimulated an increase in IL-1β concentration up to 30.0-70.0 pg/ml in nasal secretions of patients without affecting IL-1ra concentrations. On day 7 of treatment, the cytokine concentrations among the patients treated using the immunotropic drugs were the same as in the group of healthy individuals. There were no significant changes in cytokine production on day 7 in the group of patients undergoing the standard treatment. Application of proposed immunobiological medicines to ANP does not result in overproduction of proinflammatory cytokine IL-1β in nasal secretion. This confirms that these drugs are promising in the treating strategy including reduction of the risk of developing complications.
format	article
author	E. V. Bezrukova E. V. Vorobeychikov V. G. Konusova A. V. Sosunov M. M. Shamtsyan S. A. Artyushkin A. S. Simbirtsev
author_facet	E. V. Bezrukova E. V. Vorobeychikov V. G. Konusova A. V. Sosunov M. M. Shamtsyan S. A. Artyushkin A. S. Simbirtsev
author_sort	E. V. Bezrukova
title	Effect of immune drugs to treat acute viral nasopharyngitis
title_short	Effect of immune drugs to treat acute viral nasopharyngitis
title_full	Effect of immune drugs to treat acute viral nasopharyngitis
title_fullStr	Effect of immune drugs to treat acute viral nasopharyngitis
title_full_unstemmed	Effect of immune drugs to treat acute viral nasopharyngitis
title_sort	effect of immune drugs to treat acute viral nasopharyngitis
publisher	SPb RAACI
publishDate	2021
url	https://doaj.org/article/4223c9fb4215442ea3763d977e9931ad
work_keys_str_mv	AT evbezrukova effectofimmunedrugstotreatacuteviralnasopharyngitis AT evvorobeychikov effectofimmunedrugstotreatacuteviralnasopharyngitis AT vgkonusova effectofimmunedrugstotreatacuteviralnasopharyngitis AT avsosunov effectofimmunedrugstotreatacuteviralnasopharyngitis AT mmshamtsyan effectofimmunedrugstotreatacuteviralnasopharyngitis AT saartyushkin effectofimmunedrugstotreatacuteviralnasopharyngitis AT assimbirtsev effectofimmunedrugstotreatacuteviralnasopharyngitis
_version_	1718422281979428864

Effect of immune drugs to treat acute viral nasopharyngitis

Ejemplares similares